Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Anemia 2Uterine Cervical Neoplasms 1Radiation Injuries 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Erectile Dysfunction 1Drug-Related Side Effects and Adverse Reactions 1Bronchiolitis Obliterans Syndrome 1

Interventions

fludarabine phosphate 52Cyclophosphamide 45Peripheral Blood Stem Cell Transplantation 42Busulfan 37Azacitidine 34Whole-Body Irradiation 31Mycophenolic Acid 29Cytarabine 28Cyclosporine 28Tacrolimus 27Methotrexate 25Filgrastim 21Decitabine 20Radiotherapy 19Antilymphocyte Serum 19Methylprednisolone 14Melphalan 13Etoposide 13fludarabine 10Cyclosporins 9Idarubicin 8Granulocyte Colony-Stimulating Factor 8Flow Cytometry 8sargramostim 7Psychiatric Rehabilitation 7Cord Blood Stem Cell Transplantation 7merphos 6aldesleukin 6Topotecan 6Therapeutics 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Myelomonocytic, Chronic × Erythropoietin × Clear all
NCT01048034 2013-10-29

Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Nordic MDS Group

Phase 2 Completed
30 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡